The Efficacy and Safety of Bumetanide in Children with Autism Spectrum Disorder: An Updated Meta-analysis.

Researchers studied whether bumetanide (a water pill) could help reduce autism symptoms in children. They found small improvements on some autism rating scales, but results were mixed depending on which tests were used. The medication was generally safe, with side effects like increased urination and low potassium. However, the researchers couldn't conclude that bumetanide is better than current treatments for autism symptoms.

This meta-analysis examined bumetanide, a diuretic medication, as a potential treatment for autism spectrum disorder symptoms in children. The review analyzed randomized controlled trials comparing bumetanide to placebo or standard treatment. Results showed statistically significant improvements in the Childhood Autism Rating Scale (CARS) and Clinical Global Impression-Efficacy Index (CGI-EI) compared to placebo. However, no significant differences were found on the Social Responsiveness Scale, and results for social interaction and repetitive behaviors varied depending on the measurement tool used.

Common side effects included increased urination, low potassium levels, and dehydration. Despite some statistically significant findings, the authors concluded they could not establish bumetanide's superiority for treating autism symptoms.

While bumetanide showed some statistically significant improvements on certain measures, the clinical significance remains unclear. The medication appears generally safe but requires monitoring for dehydration and electrolyte imbalances. More large-scale trials needed before clinical recommendations can be made.

Authors noted they cannot conclude superiority of bumetanide despite some statistical improvements. Results varied by measurement tool used. Sample size not reported for the meta-analysis, limiting assessment of statistical power and generalizability of findings.

Autism spectrum disorder (ASD) is a complex range of neurodevelopmental disorders. The treatment of ASD is challenging since there are no approved drugs except for risperidone and aripiprazole, which have a limited effect on core symptoms and are associated with a wide range of adverse events. Bumetanide is a loop diuretic suggested to play a role in ASD symptoms by modulating the GABAergic system. This meta-analysis aims to evaluate the efficacy and safety of bumetanide on ASD symptom management.

We included randomized controlled trials comparing bumetanide with placebo or conventional treatment. Our primary outcomes included the Childhood Autism Rating Scale (CARS), Social Responsiveness Scale (SRS-2), Clinical Global Impression- Efficacy Index (CGI-EI), Social interaction (SI), repetitive behavior and restricted interests (RRB), and adverse events. Bumetanide was associated with significant improvement in CARS total score (MD = -2.28; 95% CI = [-4.07, -0.49], p = 0.01) and CGI-EI (MD = 0.27; 95% CI = [0.09, 0.44], p = 0.003) compared to placebo. However, no significant difference was found in the SRS-2 score.

Findings for SI and RRB were inconsistent depending on the pooled scales, with significant results observed when pooling SRS-2 but not when pooling ADOS. Bumetanide was generally safe and well-tolerated. Common adverse events include polyurea, hypokalemia, and dehydration. Although statistically significant improvements were observed on some measures, we cannot conclude the superiority of bumetanide in alleviating ASD symptoms.

Further large clinical trials should be conducted to determine the effect of bumetanide on different symptoms of ASD and the variation in treatment effect among different patient populations.